PTPN2 deficiency along with activation of nuclear Akt predict endocrine resistance in breast cancer.

Elin KarlssonCynthia VeenstraJon GårsjöBo NordenskjöldTommy FornanderOlle Stål

Published in: Journal of cancer research and clinical oncology (2018)

PTPN2 negatively regulates Akt signalling and loss of PTPN2 protein along with increased pAkt-n is a new potential clinical marker of endocrine treatment efficacy, which may allow for further tailored patient therapies.

Keyphrases

signaling pathway
cell proliferation
replacement therapy
combination therapy
human health
small molecule
young adults
climate change